LegitScript Findings: Explosive Ad Growth: LegitScript tracks online activity across major platforms, and our monitoring of online ads has revealed a more than 200% increase in violative or problematic GLP-1-related ads in the first half of 2024 compared to all of 2023, and a roughly 1200% increase compared to all of 2022
The best pharmacophore model was developed with eight DPP-4 inhibitors, featuring one hydrogen bond donor (HBD), one hydrogen bond acceptor, and two hydrophobic characteristics
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept"
The recent outcomes of these studies showed that significant weight-loss was achieved when using Saxenda
Akilah Weber Pierson Legislator And so if we're able to look back and see how long did those clinical trials take, that can maybe give us a little bit more information as to when we could expect the clinical trials that they are currently doing to take
